Note 8 - Subsequent Events	12 Months Ended
Dec. 31, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	Note 8: Subsequent Events For purpose of disclosure in the consolidated financial statements, the Company has evaluated subsequent events through March 29, 2022, the date the consolidated financial statements were available to be issued. Except as discussed below, management is not aware of any material events that have occurred subsequent to the balance sheet date that would require adjustment to, or disclosure in the accompanying financial statements. *Stock Option Grant* On January 3, 2022, the Company granted to executives and key personnel an aggregate of 325,000 stock options with an exercise price of $4.81. The options will vest in one year from the date of grant or annually in equal installments over four years. On January 3, 2022, the Company granted 75,000 performance-based stock options to a key personnel with an exercise price of $4.81. The options will vest upon the achievement of specified performance conditions. On January 3, 2022, the Company granted to members of the Board an aggregate of 277,500 stock options with an exercise price of $4.81. The options will vest in one year from the date of grant. On January 3, 2022, the Company granted to non-executive employees an aggregate of 23,325 stock options with an exercise price of $4.81. The options will vest annually in equal installments over four years. On January 3, 2022, the Company granted 15,000 stock options to a consultant with an exercise price of $4.81. The options will vest in one year from the date of grant. *Termination of a Material Definitive Agreement* On March 17, 2022, the Company and Sorrento Therapeutics, Inc., have mutually agreed to terminate the August 11, 2021 term sheet, due to a disagreement between the parties concerning the timing, and terms and conditions, for the entry into the license agreement. Dyadic has not incurred any early termination penalties.

Note 8 - Subsequent Events

12 Months Ended

Dec. 31, 2021

Note 8: Subsequent Events

For purpose of disclosure in the consolidated financial statements, the Company has evaluated subsequent events through March 29, 2022, the date the consolidated financial statements were available to be issued. Except as discussed below, management is not aware of any material events that have occurred subsequent to the balance sheet date that would require adjustment to, or disclosure in the accompanying financial statements.

Stock Option Grant

On January 3, 2022, the Company granted to executives and key personnel an aggregate of 325,000 stock options with an exercise price of $4.81. The options will vest in one year from the date of grant or annually in equal installments over four years.

On January 3, 2022, the Company granted 75,000 performance-based stock options to a key personnel with an exercise price of $4.81. The options will vest upon the achievement of specified performance conditions.

On January 3, 2022, the Company granted to members of the Board an aggregate of 277,500 stock options with an exercise price of $4.81. The options will vest in one year from the date of grant.

On January 3, 2022, the Company granted to non-executive employees an aggregate of 23,325 stock options with an exercise price of $4.81. The options will vest annually in equal installments over four years.

On January 3, 2022, the Company granted 15,000 stock options to a consultant with an exercise price of $4.81. The options will vest in one year from the date of grant.

Termination of a Material Definitive Agreement

On March 17, 2022, the Company and Sorrento Therapeutics, Inc., have mutually agreed to terminate the August 11, 2021 term sheet, due to a disagreement between the parties concerning the timing, and terms and conditions, for the entry into the license agreement. Dyadic has not incurred any early termination penalties.